Gano Kyle: insider trades.
Gano Kyle reported 4 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 0 sales, across 1 company.
- Transactions
- 4
- Purchases (P)
- 0
- Sales (S)
- 0
- Companies
- 1
- Name as filed
- Gano Kyle
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | Director, Officer · Chief Executive Officer | 4 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-11 | Neurocrine Biosciences Inc | A | 6,275 | $0 | 157,266 | Form 4 |
| 2026-09-11 | Neurocrine Biosciences Inc | A | 1,842 | $0 | 155,722 | Form 4 |
| 2026-09-11 | Neurocrine Biosciences Inc | F | 994 | $156.22 | 154,728 | Form 4 |
| 2026-09-11 | Neurocrine Biosciences Inc | F | 3,386 | $156.22 | 153,880 | Form 4 |
Questions
What stock did Gano Kyle buy or sell?
Gano Kyle reported 4 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 0 sales, across 1 company.
Is Gano Kyle the same person as other filers with this name?
This page covers SEC CIK 1567160 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/gano-kyle-1567160.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.